×
About 193 results

ALLMedicine™ Cancer Immunotherapy Center

Research & Reviews  91 results

Neurological complications of cancer immunotherapy (CAR T cells).
https://doi.org/10.1016/j.jns.2021.117405
Journal of the Neurological Sciences; Rubin DB, Vaitkevicius H

Mar 28th, 2021 - Chimeric antigen receptor (CAR) T cell therapy has become an indispensable tool in the treatment of advanced malignancy, however, it is associated with significant neurologic toxicity. The pathophysiology of CAR T-cell associated neurotoxicity is ...

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and E...
https://doi.org/10.1158/1078-0432.CCR-20-4001
Clinical Cancer Research : an Official Journal of the Ame... Sum E, Rapp M et. al.

Mar 27th, 2021 - CD40 agonists hold great promise for cancer immunotherapy (CIT) as they enhance dendritic cell (DC) activation and concomitant tumor-specific T-cell priming. However, the broad expression of CD40 accounts for sink and side effects, hampering the e...

Diagnosis, grading and management of toxicities from immunotherapies in children, adole...
https://doi.org/10.1038/s41571-021-00474-4 10.1111/ejh.13569
Nature Reviews. Clinical Oncology; Ragoonanan D, Khazal SJ et. al.

Feb 20th, 2021 - Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-c...

The right Timing, right combination, right sequence, and right delivery for Cancer immu...
https://doi.org/10.1016/j.jconrel.2021.01.009
Journal of Controlled Release : Official Journal of the C... Kwon M, Jung H et. al.

Jan 12th, 2021 - Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic benefit from ICIs are limited, and the efficacy of these treatments d...

New cytometry tools for immune monitoring during cancer immunotherapy.
https://doi.org/10.1002/cyto.b.21984
Cytometry. Part B, Clinical Cytometry; Sanjabi S, Lear S

Jan 12th, 2021 - The success of cancer immunotherapy (CIT) in the past decade has brought renewed excitement and the need to better understand how the human immune system functions during health and disease. Advances in single cell technologies have also inspired ...

see more →

Guidelines  1 results

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
https://www.nature.com/articles/s41591-018-0337-7
Cloughesy,T.,et al

Feb 10th, 2019 - Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune res...

see more →

Clinicaltrials.gov  99 results

Neurological complications of cancer immunotherapy (CAR T cells).
https://doi.org/10.1016/j.jns.2021.117405
Journal of the Neurological Sciences; Rubin DB, Vaitkevicius H

Mar 28th, 2021 - Chimeric antigen receptor (CAR) T cell therapy has become an indispensable tool in the treatment of advanced malignancy, however, it is associated with significant neurologic toxicity. The pathophysiology of CAR T-cell associated neurotoxicity is ...

Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and E...
https://doi.org/10.1158/1078-0432.CCR-20-4001
Clinical Cancer Research : an Official Journal of the Ame... Sum E, Rapp M et. al.

Mar 27th, 2021 - CD40 agonists hold great promise for cancer immunotherapy (CIT) as they enhance dendritic cell (DC) activation and concomitant tumor-specific T-cell priming. However, the broad expression of CD40 accounts for sink and side effects, hampering the e...

Diagnosis, grading and management of toxicities from immunotherapies in children, adole...
https://doi.org/10.1038/s41571-021-00474-4 10.1111/ejh.13569
Nature Reviews. Clinical Oncology; Ragoonanan D, Khazal SJ et. al.

Feb 20th, 2021 - Cancer immunotherapies are associated with remarkable therapeutic response rates but also with unique and severe toxicities, which potentially result in rapid deterioration in health. The number of clinical applications for novel immune effector-c...

The right Timing, right combination, right sequence, and right delivery for Cancer immu...
https://doi.org/10.1016/j.jconrel.2021.01.009
Journal of Controlled Release : Official Journal of the C... Kwon M, Jung H et. al.

Jan 12th, 2021 - Cancer immunotherapy (CI) represented by immune checkpoint inhibitors (ICIs) presents a new paradigm for cancer treatment. However, the types of cancer that attain a therapeutic benefit from ICIs are limited, and the efficacy of these treatments d...

New cytometry tools for immune monitoring during cancer immunotherapy.
https://doi.org/10.1002/cyto.b.21984
Cytometry. Part B, Clinical Cytometry; Sanjabi S, Lear S

Jan 12th, 2021 - The success of cancer immunotherapy (CIT) in the past decade has brought renewed excitement and the need to better understand how the human immune system functions during health and disease. Advances in single cell technologies have also inspired ...

see more →

News  2 results

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
https://www.nature.com/articles/s41591-018-0337-7
Cloughesy,T.,et al

Feb 10th, 2019 - Glioblastoma is the most common primary malignant brain tumor in adults and is associated with poor survival. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi-institution clinical trial to evaluate immune res...

Cancer Immunotherapy 'Has Entered Mainstream'
https://www.medscape.com/viewarticle/842032

Mar 24th, 2015 - Cancer immunotherapy takes centre stage in a series of articles about harnessing the immune system for therapy published March 25 as a special issue of Science Translational Medicine. While the articles trace the progress being made across all fie...

see more →